ABSTRACT
Patients with immunocompromising conditions are at higher risk of vaccine-preventable infections. Further, those receiving immunosuppressive disease-modifying antirheumatic drugs (DMARDs) can have variable responses to vaccines depending on which vaccine and which DMARD they are receiving.
Footnotes
Dr. Winthrop has disclosed consulting for Abbvie Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Galapagos, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Pfizer, Regeneron, Sanofi, and UCB.
Dr. Curtis has disclosed consulting, speaking, or honoraria for Abbvie, Amgen, BMS, Corona, Gilead, Janssen, Lilly, Myriad, Novartis, Pfizer, Sanofi, and Scipher.
Dr. Day reports no relevant financial relationships which, in the context of his contribution, could be perceived as a potential conflict of interest.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.
- Alvin Lee Day, MD
- Kevin L. Winthrop, MD, MPH
- Jeffrey R. Curtis, MD, MS, MPH⇑
- Professor, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
- Address:
Jeffrey R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 1720 2nd Avenue South, FOT 839, Birmingham, AL 35294; jrcurtis{at}uabmc.edu
ABSTRACT
Patients with immunocompromising conditions are at higher risk of vaccine-preventable infections. Further, those receiving immunosuppressive disease-modifying antirheumatic drugs (DMARDs) can have variable responses to vaccines depending on which vaccine and which DMARD they are receiving.
Footnotes
Dr. Winthrop has disclosed consulting for Abbvie Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Galapagos, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Pfizer, Regeneron, Sanofi, and UCB.
Dr. Curtis has disclosed consulting, speaking, or honoraria for Abbvie, Amgen, BMS, Corona, Gilead, Janssen, Lilly, Myriad, Novartis, Pfizer, Sanofi, and Scipher.
Dr. Day reports no relevant financial relationships which, in the context of his contribution, could be perceived as a potential conflict of interest.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.
In this issue
Jump to section
Related Articles
Cited By...
- Persistently reduced humoral and cellular immune response following third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients
- Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
- Rheumatology and COVID-19 at 1 year: facing the unknowns
- Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2